For producing iPS cells, the monkey fibroblasts were infected with retroviruses containing the iPS-factor genes (pMXs-hOCT3/4 [addgene: 17217], pMXs-hSOX2 [addgene: 17218], pMXs-hKLF4 [addgene: 17219], and pMXs-hc-MYC [addgene: 17220]) twice for 48 hours. The viral supernatant was produced in a GP2–293 packaging cell (Retro-X Universal Packaging System; Clontech, Mountain View, CA) culture transfected with pVSV-G and the retroviral vectors described. On the next day of the second infection, the virus-containing medium, was replaced with fresh DMEM containing 10% FBS. Six days after the viral infection, the fibroblasts were trypsinized and transferred onto mitomycin C-treated STO feeder layers at a concentration ranging from 5 × 104 to 5 × 105 cells/100-mm dish. The following day, the medium was changed to primate ES cell-maintenance medium (DMEM/F12 containing 20% KnockOut Serum Replacement [KSR; Invitrogen, Carlsbad, CA], 0.1 mM nonessential amino acids, and 0.1 mM 2-mercaptoethanol) supplemented with 5 ng/mL basic fibroblast growth factor (bFGF; Wako Chemicals, Osaka, Japan), 10 μM Y-27632, and 1 mM valproic acid sodium salt. Approximately 3 to 4 weeks after gene transduction, iPS cell colonies appeared among the feeder layers. Then they were picked up manually, dissociated mechanically, and transferred onto fresh STO feeder layers for expansion.
Established monkey iPS cells were maintained with standard protocols for primate/human ES cells. Briefly, the cells were cultured on mitomycin C-treated STO feeders in primate ES cell-maintenance medium. For passage, iPS cells were dissociated with 0.25% trypsin-1 mg/mL collagenase IV (BD Biosciences, Franklin Lakes, NJ), and some were transferred onto fresh feeder layers.